肝脏 ›› 2016, Vol. 21 ›› Issue (4): 263-266.

• 论著 • 上一篇    下一篇

锌α2糖蛋白对实验性大鼠肝癌的抑制作用

廖红雨, 于景霞, 刘婷, 陆伦根, 徐铭益   

  1. 856000 西藏 西藏山南扎囊县吉汝乡卫生院(廖红雨);上海交通大学附属第一人民医院消化科(于景霞,刘婷,陆伦根,徐铭益)
  • 收稿日期:2015-12-25 发布日期:2020-05-27
  • 通讯作者: 徐铭益,Email:xumingyi2014@163.com
  • 基金资助:
    国家科技部“十二五”重大专项(2013ZX10002004-002-003),国家自然基金面上项目(81570547),院优秀青年培养计划(061405)

Inhibition of zinc-2 glycoprotein in a rat model of hepatocellular carcinoma

LIAO Hong-yu, YU Jing-xia, LIU Ting, LU Lun-gen, XU Ming-yi   

  1. Jiru township hospital, Zhanang country, Shannan prefecture of Tibet autonomous region 856000, China;Department of Gastroenterology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai 200080, China
  • Received:2015-12-25 Published:2020-05-27
  • Contact: XU Ming-yi,Email: xumingyi2014@163.com

摘要: 目的 探讨锌α2糖蛋白(AZGP1)与肝细胞癌(HCC)发生、发展和转移的关系。方法 二乙基亚硝胺(DEN)构建肝硬化和HCC大鼠模型,以过表达AZGP1基因干扰的HepG2细胞液构建裸鼠皮下成瘤和肝原位移植模型。免疫组织化学、蛋白免疫和PCR检测AZGP1和TGFβ1的表达。结果 AZGP1 mRNA在正常肝组织、肝硬化和肝癌中的表达分别为(0.98±0.02)、(0.52±0.03)、(0.20±0.02);而TGFβ1的基因和蛋白表达在肝硬化和肝癌组织中呈现显著上调。AZGP1过表达的HepG2细胞接种裸鼠构建皮下肿瘤(HepG2-AZGP1组)。与对照组(HepG2-GFP组)比较,肿瘤大小无差异。裸鼠肝内移植术6周后,HepG2-GFP组57%和HepG2-AZGP1组14%发生肺转移(P=0.0157)。与HepG2-GFP组比较,HepG2-AZGP1组肝脏原发灶和肺转移灶结节数目明显减少,癌细胞异型性明显较轻。结论 肝硬化进展至肝癌过程中抑癌基因AZGP1发生缺失,伴随着失去阻抑TGFβ1作用。恢复AZGP1功能可能是一种新的有前途的治疗肝癌方法。

关键词: 肝细胞肝癌, 肝硬化, 锌α2糖蛋白, 转化生长因子β1

Abstract: Objective To investigate the expression of zinc-α2-glycoprotein (AZGP1) in a rat model of hepatocellular carcinoma (HCC), and its relationship with HCC progression.Methods Cirrhosis and HCC in rat models were established by diethylnitrosamine (DEN) water feeding, and subcutaneous tumor and orthotopic liver transplantation models in nude mice were constructed by injection of HepG2 cells with AZGP1 gene over-expressed interferenced vector. The expressions of AZGP1 and transforming growth factor β1 (TGFβ1) were detected by immunohistochemistry staining, westernblot (WB) and polymerase chain reaction (PCR), respectively, then the relationship among AZGP1, tumor size and metastasis rate was evaluated. Results The level of AZGP1 mRNA (0.20±0.02, p=0.003) was lower in HCC tissues than that in normal or cirrhosis tissues. Hepatic expression of AZGP1 proteins was absent or low-expressed, which was confirmed by quantitative immunohistochemical and WB analysis. Hepatic TGFβ1 gene and protein in cirrhotic and HCC tissues were significantly increased. The size of subcutaneous tumors had no difference between AZGP1 over-expressed HepG2 cells treated group (HepG2-AZGP1 group) and the control group (HepG2-GFP group). The incidence of lung metastasis was 57% in HepG2-AZGP1 group and 14% in HepG2-GFP group at week 6 after transplantation of subcutaneous tumors in nude mice. Compared with those in HepG2-GFP group, the numbers and sizes of tumor nodules in liver and lung were significantly decreased and the distinct atypia degrees of cancer cells were significantly lower in HepG2-AZGP1 group.Conclusion During the progression from cirrhosis to HCC, AZGP1 loss occurred accompanied with derepression of TGFβ1, which was proposed that function recovery of AZGP1 might be a new promising approach to reversing HCC.

Key words: Hepatocellular carcinoma (HCC), Zinc-α2-glycoprotein 1 (AZGP1), Transforming growth factor-β1 (TGF-β1), Cirrhosis